Altogether, we demonstrated that pharmacological inhibition of CDK8/19 promotes apoptosis in CML cells treated with BCR-ABLi by attenuating BCR-ABLi-induced cell cycle arrest thereby preventing the escape from apoptosis (Fig. 6D). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.